KR101701362B1 - 신경자극성 피페라진의 합성방법 - Google Patents

신경자극성 피페라진의 합성방법 Download PDF

Info

Publication number
KR101701362B1
KR101701362B1 KR1020127007653A KR20127007653A KR101701362B1 KR 101701362 B1 KR101701362 B1 KR 101701362B1 KR 1020127007653 A KR1020127007653 A KR 1020127007653A KR 20127007653 A KR20127007653 A KR 20127007653A KR 101701362 B1 KR101701362 B1 KR 101701362B1
Authority
KR
South Korea
Prior art keywords
formula
compound
reaction
alkyl
rti
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127007653A
Other languages
English (en)
Korean (ko)
Other versions
KR20120054642A (ko
Inventor
스리파티 벤카트라만
시에드 마흐무드
빙기디미 아이. 모벨
올가 라피나
켈리 버코
잉 리
조나단 살스버리
마크 매클로스
Original Assignee
뉴럴스템, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43649584&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101701362(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 뉴럴스템, 인크. filed Critical 뉴럴스템, 인크.
Publication of KR20120054642A publication Critical patent/KR20120054642A/ko
Application granted granted Critical
Publication of KR101701362B1 publication Critical patent/KR101701362B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
KR1020127007653A 2009-08-24 2010-08-24 신경자극성 피페라진의 합성방법 Active KR101701362B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23647709P 2009-08-24 2009-08-24
US61/236,477 2009-08-24
PCT/US2010/046537 WO2011028548A1 (en) 2009-08-24 2010-08-24 Synthesis of a neurostimulative piperazine

Publications (2)

Publication Number Publication Date
KR20120054642A KR20120054642A (ko) 2012-05-30
KR101701362B1 true KR101701362B1 (ko) 2017-02-01

Family

ID=43649584

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127007653A Active KR101701362B1 (ko) 2009-08-24 2010-08-24 신경자극성 피페라진의 합성방법

Country Status (22)

Country Link
US (2) US9278933B2 (enExample)
EP (1) EP2470182B1 (enExample)
JP (1) JP5727482B2 (enExample)
KR (1) KR101701362B1 (enExample)
CN (2) CN105693601A (enExample)
AU (1) AU2010289802C1 (enExample)
BR (1) BR112012004161B1 (enExample)
CA (1) CA2772080C (enExample)
CL (1) CL2012000493A1 (enExample)
DK (1) DK2470182T3 (enExample)
ES (1) ES2475721T3 (enExample)
HR (1) HRP20140621T1 (enExample)
IL (1) IL218298A (enExample)
IN (1) IN2012DN02370A (enExample)
MX (1) MX2012002335A (enExample)
NZ (1) NZ598891A (enExample)
PL (1) PL2470182T3 (enExample)
PT (1) PT2470182E (enExample)
RU (1) RU2567390C2 (enExample)
SG (1) SG178867A1 (enExample)
SI (1) SI2470182T1 (enExample)
WO (1) WO2011028548A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2012DN02370A (enExample) * 2009-08-24 2015-08-21 Neuralstem Inc
WO2018048927A1 (en) * 2016-09-12 2018-03-15 Neuralstem, Inc. Amelioration of neural deficits associated with diabetes
US20180104240A1 (en) * 2016-10-18 2018-04-19 Neuralstem, Inc. Amelioration of radiation-induced cognitive dysfunction
US10042957B2 (en) 2017-01-12 2018-08-07 Innovationdock, Inc. Devices and methods for implementing dynamic collaborative workflow systems
WO2018148733A1 (en) * 2017-02-13 2018-08-16 Neuralstem, Inc. Amelioration of certain deficiencies due to stroke
CN117377664A (zh) * 2020-12-23 2024-01-09 贝勒医学院 孤儿核受体tlx的小分子调节剂
JP2024520722A (ja) 2021-06-03 2024-05-24 オルト・ニューロサイエンス・インコーポレイテッド 不良な認知を有するうつ病患者の治療方法及びベンジルピペラジン－アミノピリジン剤の恩恵を受ける他の患者の選択
US12208096B2 (en) 2022-12-05 2025-01-28 Alto Neuroscience, Inc. Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agent
AU2023391488A1 (en) 2022-12-05 2025-05-22 Alto Neuroscience, Inc. Effective treatment of depression in patients having impaired learning and/or memory or certain eeg characteristics with a benzylpiperazine-aminopyridine agent
US12233059B2 (en) 2022-12-05 2025-02-25 Alto Neuroscience, Inc. Effective treatment of depression in patients having impaired learning and/or memory or certain EEG characteristics with a benzylpiperazine-aminopyridine agent

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004750A1 (en) * 2005-06-30 2007-01-04 Lorsbach Beth A N-substituted piperazines

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU175075B (hu) * 1977-06-30 1980-05-28 Egyt Gyogyszervegyeszeti Gyar Sposob poluchenija piperazidov piridin-karbonovoj kisloty
JPS54122283A (en) * 1978-03-13 1979-09-21 Sumitomo Chem Co Ltd Novel quinazoline derivative and its preparation
US6995162B2 (en) * 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
DE60330323D1 (de) * 2002-03-29 2010-01-14 Schering Corp Stereoselektive alkylierung von chirale 2-methyl-4-geschützte piperazinen
GB0222493D0 (en) * 2002-09-27 2002-11-06 Glaxo Group Ltd Compounds
EP1576134B1 (en) * 2002-12-09 2013-03-06 Judith Kelleher-Andersson Method for discovering neurogenic agents
BRPI0414209B8 (pt) * 2003-09-09 2021-05-25 Hoffmann La Roche derivados de 1-(2-amino-benzol)-piperazina, seus processos de preparação e seu uso, e medicamento
EP1828165B1 (en) 2004-10-29 2013-03-20 Msd K.K. Novel aminopyridine derivatives having aurora a selective inhibitory action
AU2006329007A1 (en) * 2005-12-20 2007-06-28 Novartis Ag Nicotinic acid derivatives as modulators of metabotropic glutamate receptors
IN2012DN02370A (enExample) * 2009-08-24 2015-08-21 Neuralstem Inc

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070004750A1 (en) * 2005-06-30 2007-01-04 Lorsbach Beth A N-substituted piperazines

Also Published As

Publication number Publication date
RU2012111227A (ru) 2013-10-10
HK1172844A1 (en) 2013-05-03
US9278933B2 (en) 2016-03-08
JP2013502462A (ja) 2013-01-24
BR112012004161A2 (pt) 2016-03-29
AU2010289802B2 (en) 2014-10-02
IL218298A0 (en) 2012-04-30
EP2470182A4 (en) 2013-04-24
EP2470182B1 (en) 2014-06-04
PL2470182T3 (pl) 2015-05-29
BR112012004161B1 (pt) 2020-04-07
AU2010289802C1 (en) 2015-04-16
MX2012002335A (es) 2012-07-04
US20160090358A1 (en) 2016-03-31
IL218298A (en) 2017-03-30
CL2012000493A1 (es) 2012-09-28
US20130005974A1 (en) 2013-01-03
EP2470182A1 (en) 2012-07-04
CN102711764A (zh) 2012-10-03
AU2010289802A1 (en) 2012-04-12
KR20120054642A (ko) 2012-05-30
NZ598891A (en) 2014-05-30
DK2470182T3 (da) 2014-07-21
HRP20140621T1 (hr) 2014-11-21
ES2475721T3 (es) 2014-07-11
JP5727482B2 (ja) 2015-06-03
SI2470182T1 (sl) 2014-10-30
WO2011028548A1 (en) 2011-03-10
US9481649B2 (en) 2016-11-01
CN105693601A (zh) 2016-06-22
SG178867A1 (en) 2012-04-27
IN2012DN02370A (enExample) 2015-08-21
CA2772080A1 (en) 2011-03-10
CA2772080C (en) 2017-05-30
PT2470182E (pt) 2014-07-24
RU2567390C2 (ru) 2015-11-10

Similar Documents

Publication Publication Date Title
KR101701362B1 (ko) 신경자극성 피페라진의 합성방법
KR20150020287A (ko) 특정 2-(피리딘-3-일)티아졸의 제조 방법
BR112012002251B1 (pt) processo para a fabricação do composto de fórmula (1), compostos, composição, método analítico e processo para a fabricação do composto (i)
CN107531677A (zh) 用于制备托匹司他及其中间体的方法
DK2948441T3 (en) PROCEDURE FOR PREPARING 1- (4- (4- (3,4-DICHLOR-2-FLUORPHENYLAMINO) -7-METHOXYQUINAZOLIN-6-YLOXY) PIPERIDIN-1-YL) PROP-2-EN-1-ON
KR20220097388A (ko) 헤테로시클릭 아미드계 화합물, 이의 약학적으로 허용 가능한 염 및 이의 제조 방법 및 용도
KR20120136296A (ko) ４-｛３-〔시스-헥사히드로시클로펜타〔ｃ〕피롤-２（１ｈ）-일〕프로폭시｝벤즈아미드 히드로클로라이드의 합성 방법, 및 이의 결정형, 및 이를 함유하는 약학적 조성물
US7893269B2 (en) Process for the manufacture of 3-hydroxy-N-alkyl-1-cycloalky1-6-alkyl-4-oxo-1,4-dihydropyridine-2-carboxamide and its related analogues
KR101316653B1 (ko) 헤테로고리 화합물의 제조방법
AU2005202345A1 (en) Process for the Synthesis of Thalidomide
KR102702677B1 (ko) 피마살탄 및 그의 제조 중간체의 제조방법
JP6325139B2 (ja) カルムスチンの安全で効率的な製造方法
HK1172844B (en) Synthesis of a neurostimulative piperazine
RU2733731C1 (ru) Способ получения промежуточных продуктов для синтеза каланолидов и их аналогов
KR101868438B1 (ko) 아미드 유도체의 제조방법
JP2025537627A (ja) セレン含有複素環式化合物およびその使用
Li et al. Soluble poly (ethylene glycol) supported efficient synthesis of 2, 5‐disubstituted 1, 3, 4‐oxadiazoles and 1, 3, 4‐thiadiazoles
JP2010502607A (ja) （３−アルキル−５−ピペリジン−１−イル−３，３ａ−ジヒドロ−ピラゾロ［１，５−ａ］ピリミジン−７−イル）−アミノ誘導体および中間体の合成のための方法および合成のための中間体
WO1994002481A1 (fr) Derive d'imidazonaphtyridine
JPH09157237A (ja) Ｎ−低級アルキル−２−アミノ−３，３−ジメトキシ−プロパンアミドおよびその製造方法
JPH0625148B2 (ja) ２−アミノイミダゾ−ルまたはその塩の製造法
WO2001019848A1 (fr) Nouveaux procedes de production de composes peptidiques

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20200103

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 10